AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22170360 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat intake (62.7 g per 1000 kcal in quintile 5)
Number of subjects: 492186
Study 22170360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intakes of benzo(a)pyrene (BaP) and 2-amino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine (PhIP)
Number of subjects: 492186
Study 22170360 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention or control reported for clear cell subtype
Number of subjects: 492186
Study 22170723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin replacement therapy (0.08 mg/kg·d by twice daily sc injections for 6 months) in SH group
Number of subjects: 24
Study 22170723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin replacement therapy (0.08 mg/kg·d by twice daily sc injections for 6 months) in MH group
Number of subjects: 24
Study 22170723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin replacement therapy in SH group
Number of subjects: 24
Study 22170723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin replacement therapy in MH group
Number of subjects: 24
Study 22171692 — intervention group
Group type: COMPARATOR
Intervention: T2D patients (SET1)
Number of subjects: 92
Study 22171692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified glucose control (SET2)
Number of subjects: 92
Study 22171692 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment (in both sets)
Number of subjects: 92
Study 22171697 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (25 fractions of 2 Gy with concurrent capecitabine) followed by Transanal Endoscopic Microsurgery (TEM)
Number of subjects: 0
Study 22172461 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 0
Study 22172590 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-h nocturnal in-center thrice weekly hemodialysis (NHD)
Number of subjects: 120
Study 22172590 — intervention group
Group type: COMPARATOR
Intervention: 4-h thrice weekly conventional hemodialysis (CHD)
Number of subjects: 120
Study 22173060 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² intravenously once a week for 4 weeks) followed by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone every 3 weeks for 4 cycles)
Number of subjects: 70
Study 22173060 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and CHOP
Number of subjects: 70
Study 22173060 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 70
Study 22173935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound contrast (UC) with real-time perfusion (RTP)
Number of subjects: 51
Study 22173935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound contrast (UC) during BSE
Number of subjects: 51
Study 22173935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound contrast (UC) at rest and with supine BSE
Number of subjects: 51
Study 22174351 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004 alone
Number of subjects: 0
Study 22174351 — intervention group
Group type: COMPARATOR
Intervention: MAP0004 plus ketoconazole
Number of subjects: 0
Study 22174351 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004 with ketoconazole
Number of subjects: 0
Study 22174351 — intervention group
Group type: COMPARATOR
Intervention: MAP0004 without ketoconazole
Number of subjects: 0
Study 22174351 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004
Number of subjects: 0
Study 22174752 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) intensification for 48 weeks
Number of subjects: 4
Study 22176583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand activity prompted by health care aides (twice daily during care routines)
Number of subjects: 0
Study 22176583 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 22176869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5mg once daily continuously with 4-week cycle
Number of subjects: 56
Study 22177085 — intervention group
Group type: EXPERIMENTAL
Intervention: High cereal-fiber diet (HCF, 43 g/day)
Number of subjects: 69
Study 22177085 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet (HP, 28% of energy-intake, cereal-fiber 14 g/day)
Number of subjects: 69
Study 22177085 — intervention group
Group type: COMPARATOR
Intervention: Moderately high cereal fiber/protein diet (MIX, protein 23% of energy-intake, cereal-fiber 26 g/day)
Number of subjects: 69
Study 22177085 — intervention group
Group type: COMPARATOR
Intervention: Control diet (cereal-fiber 14 g/day)
Number of subjects: 69
Study 22178121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) and cisplatin (100 mg/m(2)) on days 1, 22, and 43 of radiation (70 Gy) with intensity-modulated radiation therapy over 33 days, followed by bevacizumab (15 mg/kg) and cisplatin (80 mg/m(2)) on days 64, 85, and 106 after radiation, and fluorouracil (1000 mg/m(2) per day) on days 64-67, 85-88, and 106-109 after radiation.
Number of subjects: 46
Study 22178570 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex FBE kindreds
Number of subjects: 1145
Study 22178570 — intervention group
Group type: COMPARATOR
Intervention: Nonfamilial EAC cases
Number of subjects: 1145
Study 22179034 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT implantation
Number of subjects: 2438
Study 22179536 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase therapy (300 to 1200 μg) delivered locally into occlusions via over-the-wire balloon system or fine-cross microcatheter for 30 minutes.
Number of subjects: 20
Study 22179536 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase therapy (300 to 1200 μg) delivered locally into occlusions.
Number of subjects: 20
Study 22179957 — intervention group
Group type: EXPERIMENTAL
Intervention: CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator)
Number of subjects: 6510
Study 22179957 — intervention group
Group type: EXPERIMENTAL
Intervention: CUN-BAE
Number of subjects: 6510
Study 22180164 — intervention group
Group type: EXPERIMENTAL
Intervention: R-EPOCH
Number of subjects: 150
Study 22180164 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 150
Study 22180427 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 32
Study 22180427 — intervention group
Group type: COMPARATOR
Intervention: Desferrioxamine
Number of subjects: 32
Study 22180427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of deferiprone and desferrioxamine
Number of subjects: 32
Study 22180427 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone-containing regimens
Number of subjects: 32
Study 22182397 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% dermal patch) after pretreatment with lidocaine 2.5%/prilocaine 2.5% cream
Number of subjects: 24
Study 22182397 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% dermal patch)
Number of subjects: 24
Study 22182735 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test (RDT)
Number of subjects: 22052
Study 22182735 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopy
Number of subjects: 22052
Study 22183039 — intervention group
Group type: COMPARATOR
Intervention: Presumptive diagnosis of malaria (control)
Number of subjects: 52116
Study 22183039 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopy
Number of subjects: 52116
Study 22183039 — intervention group
Group type: EXPERIMENTAL
Intervention: RDT
Number of subjects: 52116
Study 22183105 — intervention group
Group type: EXPERIMENTAL
Intervention: MonoMax® suture material
Number of subjects: 150
Study 22183105 — intervention group
Group type: COMPARATOR
Intervention: MonoPlus® or PDS® (Control)
Number of subjects: 150
Study 22183907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative laryngeal electromyography (LEMG)
Number of subjects: 25
Study 22184407 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-ADA treatment
Number of subjects: 0
Study 22184407 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 0
Study 22184407 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation
Number of subjects: 0
Study 22184407 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated murine ADA(-/-) Tregs
Number of subjects: 0
Study 22185672 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (standard treatment)
Number of subjects: 50
Study 22185681 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of 80 mg acetate methylprednisolone
Number of subjects: 17
Study 22185681 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of 80 mg acetate methylprednisolone
Number of subjects: 17
Study 22185733 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS)
Number of subjects: 32
Study 22185733 — intervention group
Group type: COMPARATOR
Intervention: Decongestion (0.05% oxymetazoline chloride applied as an aerosol spray)
Number of subjects: 32
Study 22185733 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestion with ENDS
Number of subjects: 32
Study 22185733 — intervention group
Group type: COMPARATOR
Intervention: Basal condition
Number of subjects: 32
Study 22186627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.5 mg/m2) administered twice a week for 2 consecutive weeks (days 1, 4, 8, and 11) followed by a 10-day rest period.
Number of subjects: 18
Study 22186627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.5 mg/m2) administered as described above.
Number of subjects: 18
Study 22188558 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to abdomen
Number of subjects: 72
Study 22188558 — intervention group
Group type: COMPARATOR
Intervention: 1.62% testosterone gel applied to abdomen with t-shirt barrier
Number of subjects: 72
Study 22188558 — intervention group
Group type: COMPARATOR
Intervention: 1.62% testosterone gel applied to upper arms and shoulders with t-shirt barrier
Number of subjects: 72
Study 22188558 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to upper arms and shoulders or combination with abdomen without t-shirt barrier
Number of subjects: 72
Study 22189084 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400mg)
Number of subjects: 0
Study 22189340 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ertapenem
Number of subjects: 23
Study 22190166 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-tiered trauma team activation protocol
Number of subjects: 1812
Study 22190606 — intervention group
Group type: COMPARATOR
Intervention: 200 mg of etravirine/12 h (Control)
Number of subjects: 8
Study 22190606 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of etravirine/24 h (Intervention)
Number of subjects: 8
Study 22190676 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 322
Study 22190676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 322
Study 22190676 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 322
Study 22190676 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets (low-fat, Mediterranean, low-carbohydrate)
Number of subjects: 322
Study 22192371 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V Everolimus Eluting Coronary Stent System (EECSS)
Number of subjects: 5054
Study 22192795 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer vacation
Number of subjects: 0
Study 22192795 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 0
Study 22192795 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval effects
Number of subjects: 0
Study 22192795 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer effect on BMI
Number of subjects: 0
Study 22192795 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-Z and BMI-Z velocities
Number of subjects: 0
Study 22192966 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 INH-nf, 1,000 U intravenously
Number of subjects: 113
Study 22197613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vatalanib 1250 mg orally once daily
Number of subjects: 47
Study 22197618 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcoronary Ross operation
Number of subjects: 203
Study 22198152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NAM)
Number of subjects: 0
Study 22198152 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-527 (SIRT1 inhibitor)
Number of subjects: 0
Study 22198152 — intervention group
Group type: COMPARATOR
Intervention: Control (non-cultured competitor cells)
Number of subjects: 0
Study 22198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphodepletion induced by chemo-radiotherapy
Number of subjects: 27
Study 22198310 — intervention group
Group type: EXPERIMENTAL
Intervention: PR1 responses in CML patients
Number of subjects: 27
Study 22198310 — intervention group
Group type: EXPERIMENTAL
Intervention: PR1 responses in ALL patients
Number of subjects: 27
Study 22198310 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1-126 peptide vaccination
Number of subjects: 27
Study 22198309 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α-2b + imatinib
Number of subjects: 8
Study 22198412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg oral daily) plus Bevacizumab (10 mg/kg IV every 2 weeks)
Number of subjects: 52
Study 22198412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus Bevacizumab
Number of subjects: 52
Study 22198787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test (RDT) for malaria
Number of subjects: 5670
Study 22198787 — intervention group
Group type: EXPERIMENTAL
Intervention: Reattendance after negative RDT
Number of subjects: 5670
Study 22198787 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe illness outcomes
Number of subjects: 5670
Study 22198787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality outcomes
Number of subjects: 5670
Study 22202188 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 1-Hz to the undamaged right hemisphere
Number of subjects: 0
Study 22202188 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) followed by speech therapy (constraint-induced language therapy)
Number of subjects: 0
Study 22203761 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous GM-CSF during cycle 1 and intravenous GM-CSF during cycle 4
Number of subjects: 151
Study 22203761 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous GM-CSF at both cycles
Number of subjects: 151
Study 22203761 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-GD2 monoclonal antibody and GM-CSF
Number of subjects: 151
Study 22203761 — intervention group
Group type: COMPARATOR
Intervention: Second-line cyclophosphamide-based therapy before protocol entry
Number of subjects: 151
Study 22206353 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol treatment
Number of subjects: 3313
Study 22206473 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenously released glucose, insulin, GLP-1, ghrelin
Number of subjects: 23
Study 22206473 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 level at 30 min
Number of subjects: 23
Study 22206473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin levels
Number of subjects: 23
Study 22206473 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in glucose level at 30 min
Number of subjects: 23
Study 22206473 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 0-30 min AUC
Number of subjects: 23
Study 22206473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin 0-120 min AUC
Number of subjects: 23
Study 22206581 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17P) 250 mg in 1 mL castor oil, weekly intramuscular injection
Number of subjects: 12
Study 22206581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL castor oil), weekly intramuscular injection
Number of subjects: 12
Study 22206727 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 in inflamed patients (n = 46)
Number of subjects: 100
Study 22206727 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 in noninflamed patients (n = 54)
Number of subjects: 100
Study 22206727 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ1-42/40 in noninflamed patients (n = 54)
Number of subjects: 100
Study 22206727 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid-β levels
Number of subjects: 100
Study 22206727 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 100
Study 22207464 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric MRI and MRS
Number of subjects: 24
Study 22207464 — intervention group
Group type: COMPARATOR
Intervention: Control (term infants)
Number of subjects: 24
Study 22207464 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric MRI
Number of subjects: 24
Study 22209268 — intervention group
Group type: EXPERIMENTAL
Intervention: ABSORB BVS 1.1 implantation at 6 months follow-up
Number of subjects: 58
Study 22209268 — intervention group
Group type: EXPERIMENTAL
Intervention: ABSORB BVS 1.1 implantation at 12 months follow-up
Number of subjects: 58
Study 22210086 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with docetaxel
Number of subjects: 25
Study 22210091 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab at 6 mg/kg every 14 days (cycle length = 28 days)
Number of subjects: 20
Study 22210091 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 20
Study 22211928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus QD at 0.1mg/kg/day
Number of subjects: 346
Study 22211928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus QD
Number of subjects: 346
Study 22212516 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP therapy
Number of subjects: 40
Study 22212516 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 22212516 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6, IL-7, IL-8, IL-10 (inflammatory markers)
Number of subjects: 40
Study 22212516 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 40
Study 22212857 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22212936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib administration after curative treatment (resection or ablation)
Number of subjects: 0
Study 22212936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-α2a long-term maintenance therapy
Number of subjects: 0
Study 22213129 — intervention group
Group type: EXPERIMENTAL
Intervention: Effusion
Number of subjects: 177
Study 22213129 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent cartilage damage in the same subregion
Number of subjects: 177
Study 22213129 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline meniscal extrusion
Number of subjects: 177
Study 22213129 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent bone marrow lesions
Number of subjects: 177
Study 22213129 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent cartilage damage
Number of subjects: 177
Study 22215271 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based buprenorphine-naloxone treatment
Number of subjects: 0
Study 22215271 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based buprenorphine-naloxone treatment with 50% price reduction
Number of subjects: 0
Study 22215271 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based buprenorphine-naloxone treatment with alternative quality-of-life weights
Number of subjects: 0
Study 22215271 — intervention group
Group type: EXPERIMENTAL
Intervention: Research to reduce quality-of-life uncertainties
Number of subjects: 0
Study 22215271 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 22216169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1 (n=2,274) undergoing first-time diagnostic coronary angiography
Number of subjects: 3165
Study 22216169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2 (n=590) with acute myocardial infarction requiring percutaneous revascularization
Number of subjects: 3165
Study 22216169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 3 (n=301) with known left main coronary artery disease
Number of subjects: 3165
Study 22216169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1 (n=2,274)
Number of subjects: 3165
Study 22217562 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured by past-year physical activity questionnaire score)
Number of subjects: 464
Study 22217879 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable blood pressure (no more than a 1-mm Hg change per month)
Number of subjects: 10245
Study 22217879 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing blood pressure (over 1-mm Hg per month)
Number of subjects: 10245
Study 22217879 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing blood pressure (less than 1-mm Hg per month)
Number of subjects: 10245
Study 22217879 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cardioprotective drugs for 1 month or more
Number of subjects: 10245
Study 22217879 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group for comparison)
Number of subjects: 10245
Study 22217965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle behaviors before IVF cycle
Number of subjects: 118
Study 22217965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle behaviors during ART cycle
Number of subjects: 118
Study 22218159 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing (≥7 h compared with <1 h/d)
Number of subjects: 240819
Study 22218159 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing (≥7 h/d) among adults reporting high levels of MVPA (>7 h/wk)
Number of subjects: 240819
Study 22218721 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly low-dose (25,000 IU) vitamin A
Number of subjects: 62662
Study 22218721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62662
Study 22218909 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine at 1,000 mg/m(2) and oxaliplatin at 100 mg/m(2) every 2 weeks
Number of subjects: 28
Study 22219223 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyfunctional, highly differentiated effector CD4(+) T-cell responses targeting antigens of underlying co-infection
Number of subjects: 0